{"id":58129,"date":"2025-11-06T11:16:20","date_gmt":"2025-11-06T11:16:20","guid":{"rendered":"https:\/\/ibima.eu\/?page_id=58129"},"modified":"2026-11-06T11:27:50","modified_gmt":"2026-11-06T11:27:50","slug":"ep-permed-cgt4pm2027","status":"publish","type":"page","link":"https:\/\/ibima.eu\/en\/ep-permed-cgt4pm2027\/","title":{"rendered":"EP PerMed &#8211; CGT4PM2027"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; admin_label=\u00bbsection\u00bb _builder_version=\u00bb4.25.1&#8243; custom_padding=\u00bb||0px|||\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_5,3_5,1_5&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb21px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][et_pb_column type=\u00bb3_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2025\/09\/EPPerMed_Logo_.png\u00bb title_text=\u00bbEPPerMed_Logo_\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb54%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb26px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb59px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbEP PerMed \u2013 Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3&#8243; title_line_height=\u00bb1.3em\u00bb module_alignment=\u00bbcenter\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.7&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb1px|-78px|||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p data-pm-slice=\"1 1 []\" style=\"text-align: justify;\"><span>La Asociaci\u00f3n Europea <\/span><strong><span>EP PerMed<\/span><\/strong><span> ha anunciado la convocatoria transnacional <\/span><strong><span>CGT4PM2027 \u2013 Cell and Gene Therapy for Personalised Medicine<\/span><\/strong><span>, destinada a financiar proyectos internacionales de investigaci\u00f3n innovadora centrados en el desarrollo y validaci\u00f3n de nuevas terapias celulares y g\u00e9nicas aplicadas a la medicina personalizada.<\/span><\/p>\n<p>[\/et_pb_text][et_pb_heading title=\u00bbObjetivos de la convocatoria\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\u00bbrow\u00bb _builder_version=\u00bb4.25.1&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb77.1%\u00bb custom_margin=\u00bb|-259px||161px||\u00bb custom_padding=\u00bb|0px||9px||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.16&#8243; custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.7&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb11px|-78px|||false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p data-pm-slice=\"1 1 []\" style=\"text-align: justify;\"><span>Los proyectos deber\u00e1 abordar el <\/span><strong><span>desarrollo y validaci\u00f3n de terapias celulares y g\u00e9nicas novedosas e innovadoras mediante enfoques de medicina personalizada<\/span><\/strong><span>.<\/span><\/p>\n<p style=\"text-align: justify;\">Las propuestas deber\u00e1n incorporar al menos una de las siguientes aproximaciones terap\u00e9uticas:<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul data-spread=\"false\" style=\"text-align: justify;\">\n<li><strong><span>Terapias celulares som\u00e1ticas<\/span><\/strong><span> (<\/span><em><span>somatic cell therapeutics<\/span><\/em><span>).<\/span><\/li>\n<li><strong><span>Terapias g\u00e9nicas<\/span><\/strong><span> (<\/span><em><span>gene therapeutics<\/span><\/em><span>).<\/span><\/li>\n<li><strong><span>Terapias combinadas celulares y g\u00e9nicas<\/span><\/strong><span> (<\/span><em><span>combined cell- and gene therapeutics<\/span><\/em><span>).<\/span><\/li>\n<li><strong><span>Nuevos productos biol\u00f3gicos<\/span><\/strong><span>, como ARN mensajero (ARNm), otros m\u00e9todos basados en \u00e1cidos nucleicos y ves\u00edculas extracelulares utilizadas como veh\u00edculos para procedimientos terap\u00e9uticos basados en genes.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><span>La convocatoria est\u00e1 abierta a todas las \u00e1reas de enfermedad, sin establecer prioridades ni limitaciones por especialidad m\u00e9dica o patolog\u00eda.<\/span><\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb10px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbAspectos a tener en cuenta\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p data-pm-slice=\"1 1 []\" style=\"text-align: justify;\"><span>EP PerMed fomenta que los proyectos incorporen <\/span><strong><span>colaboraciones interdisciplinares<\/span><\/strong><span>, integrando diferentes capacidades cient\u00edficas, cl\u00ednicas y tecnol\u00f3gicas relacionadas con la investigaci\u00f3n propuesta. Espec\u00edficamente la convocatoria buscar\u00e1:<\/span><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul data-spread=\"false\" data-pm-slice=\"3 1 []\" style=\"text-align: justify;\">\n<li>\n<p><strong><span>Investigaci\u00f3n precl\u00ednica y cl\u00ednica<\/span><\/strong><span>, para el desarrollo y validaci\u00f3n de las aproximaciones terap\u00e9uticas propuestas.<\/span><\/p>\n<\/li>\n<li>\n<p><strong><span>Bioinform\u00e1tica, inform\u00e1tica sanitaria y ciencia de datos<\/span><\/strong><span>, como disciplinas complementarias a la investigaci\u00f3n.<\/span><\/p>\n<\/li>\n<li>\n<p><strong><span>Investigaci\u00f3n sobre aspectos \u00e9ticos, legales y sociales (ELSA)<\/span><\/strong><span> relacionados con la medicina personalizada.<\/span><\/p>\n<\/li>\n<li>\n<p><strong><span>Investigaci\u00f3n en implementaci\u00f3n y econom\u00eda de la salud<\/span><\/strong><span>, vinculada al proyecto.<\/span><\/p>\n<\/li>\n<li>\n<p><strong><span>An\u00e1lisis de la perspectiva de los usuarios finales<\/span><\/strong><span>, para facilitar la implementaci\u00f3n de la medicina personalizada.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span>Asimismo, se fomenta la <\/span><strong><span>colaboraci\u00f3n intersectorial<\/span><\/strong><span>, incluyendo empresas y pymes, agencias reguladoras, organismos de evaluaci\u00f3n de tecnolog\u00edas sanitarias (HTA) y organizaciones de pacientes.<\/span><\/p>\n<p style=\"text-align: justify;\"><em><span>La convocatoria no se limita a una enfermedad concreta. El elemento central de las propuestas ser\u00e1 la terapia celular o g\u00e9nica innovadora que se pretende desarrollar y validar, junto con su aplicaci\u00f3n a la medicina personalizada.<\/span><\/em><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb14px|auto|-13px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbCondiciones generales\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb15px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb103.7%\u00bb custom_margin=\u00bb|-44px||||\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul data-spread=\"false\" data-pm-slice=\"3 1 []\">\n<li>\n<p style=\"text-align: justify;\"><strong><span>Formato de solicitud:<\/span><\/strong><span> en dos fases (<\/span><em><span>pre-proposal<\/span><\/em><span> y <\/span><em><span>full proposal<\/span><\/em><span>).<\/span><\/p>\n<\/li>\n<li style=\"text-align: justify;\"><strong><span>Presupuesto global indicativo:<\/span><\/strong><span> aproximadamente 33 millones de euros.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Pa\u00edses participantes en la preparaci\u00f3n de la convocatoria:<\/span><\/strong><span> Alemania, Austria, B\u00e9lgica, Canad\u00e1, Chequia, Eslovaquia, Espa\u00f1a, Estonia, Finlandia, Francia, Hungr\u00eda, Irlanda, Israel, Italia, Letonia, Lituania, Luxemburgo, Noruega, Pa\u00edses Bajos, Polonia, Portugal, Ruman\u00eda, Suecia y Turqu\u00eda.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Colaboraci\u00f3n intersectorial:<\/span><\/strong><span> se fomenta la participaci\u00f3n de equipos acad\u00e9micos, cl\u00ednicos, de salud p\u00fablica y del sector privado.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Duraci\u00f3n de los proyectos:<\/span><\/strong><span> m\u00e1ximo 36 meses.\u00a0<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Financiaci\u00f3n espa\u00f1ola y andaluza:<\/span><\/strong><span> la convocatoria contempla la participaci\u00f3n de los siguientes organismos financiadores:<\/span>\n<ul data-spread=\"false\" data-pm-slice=\"3 1 []\">\n<li><strong><span>Instituto de Salud Carlos III (ISCIII). <\/span><\/strong>La financiaci\u00f3n m\u00e1xima depender\u00e1 de su papel en el consorcio y del n\u00famero de socios espa\u00f1oles que soliciten financiaci\u00f3n:\n<ul data-spread=\"true\">\n<li><strong><span>Como socio (no coordinador):<\/span><\/strong>\n<ul data-spread=\"false\">\n<li><strong><span>200.000 \u20ac<\/span><\/strong><span>, si hay un \u00fanico socio espa\u00f1ol solicitando financiaci\u00f3n al ISCIII.<\/span><\/li>\n<li><strong><span>250.000 \u20ac<\/span><\/strong><span>, si hay dos socios espa\u00f1oles solicitando financiaci\u00f3n al ISCIII (a dividir entre ambos socios).<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong><span>Como coordinador:<\/span><\/strong>\n<ul data-spread=\"false\">\n<li><strong><span>275.000 \u20ac<\/span><\/strong><span>, si el coordinador es el \u00fanico socio espa\u00f1ol de la propuesta.<\/span><\/li>\n<li><strong><span>350.000 \u20ac<\/span><\/strong><span>, si participa un socio espa\u00f1ol adicional, y ambos solicitan financiaci\u00f3n al ISCIII (a dividir entre ambos coordinador y socio).<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li><strong><span>Consejer\u00eda de Presidencia, Sanidad y Emergencias de la Junta de Andaluc\u00eda (CPSEJA).<\/span><\/strong>\n<ul data-spread=\"false\" data-pm-slice=\"3 1 []\">\n<li><strong><span>Como socio (no coordinador): 125.0<\/span><\/strong><strong><span>00 \u20ac<\/span><\/strong><\/li>\n<li><strong><span>Como socio coordinador: 250.000 \u20ac<\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<li><strong><span>Networking y b\u00fasqueda de socios:<\/span><\/strong> los investigadores interesados en establecer colaboraciones internacionales y formar consorcios podr\u00e1n utilizar la plataforma <a href=\"https:\/\/www.b2match.com\/e\/eppermed-partnering\"><span>EP PerMed Partnering Tool<\/span><\/a>.<\/li>\n<li style=\"text-align: justify;\">La convocatoria tambi\u00e9n contempla la colaboraci\u00f3n con <strong>Breakthrough T1D<\/strong> para proyectos centrados en diabetes tipo 1. Esta organizaci\u00f3n ofrece una posible v\u00eda de apoyo para investigadores de cualquier pa\u00eds que participen como socios con financiaci\u00f3n propia en propuestas seleccionadas.<\/li>\n<li style=\"text-align: justify;\">Asimismo, mediante la colaboraci\u00f3n con <strong>Xjenza Malta<\/strong>, investigadores establecidos en Malta podr\u00e1n optar a ayudas de hasta 300.000 euros por proyecto a trav\u00e9s del programa Access2Partnerships, sujetas a las condiciones y aprobaci\u00f3n nacional correspondientes.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb min_height=\u00bb317px\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbfechas clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul data-spread=\"false\">\n<li style=\"text-align: justify;\"><span><\/span><strong><span>3 de diciembre de 2026:<\/span><\/strong> jornada informativa (<em><span>Information Day<\/span><\/em>).<\/li>\n<li style=\"text-align: justify;\"><strong><span>20 de enero de 2027, 14:00 CET:<\/span><\/strong> fecha l\u00edmite para la presentaci\u00f3n de pre-propuestas.<\/li>\n<li style=\"text-align: justify;\"><strong><span>Principios de abril de 2027:<\/span><\/strong> comunicaci\u00f3n de los resultados de evaluaci\u00f3n de pre-propuestas e invitaci\u00f3n a presentar propuestas completas.<\/li>\n<li style=\"text-align: justify;\"><strong><span>25 de mayo de 2027, 14:00 CEST:<\/span><\/strong> fecha l\u00edmite para la presentaci\u00f3n de propuestas completas.<\/li>\n<li style=\"text-align: justify;\"><strong><span>Principios de agosto de 2027:<\/span><\/strong> fase de r\u00e9plica (<em><span>rebuttal<\/span><\/em>).<\/li>\n<li style=\"text-align: justify;\"><strong><span>Octubre de 2027:<\/span><\/strong> comunicaci\u00f3n prevista de las decisiones de financiaci\u00f3n.<\/li>\n<li style=\"text-align: justify;\"><strong><span>Finales de 2027 \/ principios de 2028:<\/span><\/strong> inicio previsto de los proyectos, sujeto a los procedimientos nacionales y regionales de financiaci\u00f3n.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb-23px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbDocumentaci\u00f3n y enlaces clave\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb-13px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb0px||24px||false|false\u00bb custom_padding=\u00bb||0px|11px||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul data-spread=\"false\" data-pm-slice=\"3 3 []\">\n<li><strong><a href=\"https:\/\/www.eppermed.eu\/funding-projects\/calls\/jtc2027\/\"><span>Web EP PerMed \u2013 CGT4PM2027<\/span><\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.eppermed.eu\/funding-projects\/calls\/jtc2027\/\"><span><\/span><\/a><\/strong><a href=\"https:\/\/www.eppermed.eu\/wp-content\/uploads\/EPPerMed_JTC2027_CGT4PM2027_Call-Text.pdf\">Texto del anuncio oficial\u00a0<\/a><\/li>\n<li><strong><a href=\"https:\/\/www.b2match.com\/e\/eppermed-partnering\"><span>Plataforma de matchmaking \u2013 EP PerMed Partnering Tool<\/span><\/a><\/strong><\/li>\n<li><a href=\"https:\/\/www.eppermed.eu\/wp-content\/uploads\/EPPerMed_JTC2027_CGT4PM2027_GuidelinesApplicants.pdf\"><strong><span>Guidelines for Applicants<\/span><\/strong><\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#195e7f\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,1_4,1_4,1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/Logoblancofondoazul.jpg\u00bb title_text=\u00bbLogoblancofondoazul\u00bb force_fullwidth=\u00bbon\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb transform_scale_tablet=\u00bb202%|202%\u00bb transform_scale_phone=\u00bb202%|202%\u00bb transform_scale_last_edited=\u00bbon|tablet\u00bb transform_translate_tablet=\u00bb75px|25px\u00bb transform_translate_phone=\u00bb85px|-15px\u00bb transform_translate_last_edited=\u00bbon|phone\u00bb transform_translate_linked_tablet=\u00bboff\u00bb transform_rotate_tablet=\u00bb\u00bb transform_rotate_phone=\u00bb\u00bb transform_rotate_last_edited=\u00bbon|tablet\u00bb transform_skew_tablet=\u00bb\u00bb transform_skew_phone=\u00bb\u00bb transform_skew_last_edited=\u00bbon|tablet\u00bb transform_origin_tablet=\u00bb\u00bb transform_origin_phone=\u00bb\u00bb transform_origin_last_edited=\u00bbon|tablet\u00bb transform_styles_last_edited=\u00bbon|phone\u00bb min_height_tablet=\u00bb\u00bb min_height_phone=\u00bb\u00bb min_height_last_edited=\u00bbon|desktop\u00bb custom_margin_tablet=\u00bb||0px|-5px|false|false\u00bb custom_margin_phone=\u00bb||30px|-17px|false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb custom_padding=\u00bb|200px|||false|false\u00bb custom_padding_tablet=\u00bb0px|200px|||false|false\u00bb custom_padding_phone=\u00bb|200px|||false|false\u00bb custom_padding_last_edited=\u00bbon|desktop\u00bb transform_styles_tablet=\u00bb\u00bb transform_styles_phone=\u00bb\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb14px|||-11%|false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p class=\"x_MsoNormal\" style=\"text-align: left;\"><span style=\"color: #ffffff;\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px; float: left;\" \/>Avenida Severo Ochoa, 35, 29590, M\u00e1laga<\/span><\/p>\n<p style=\"color: #ffffff;\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/phone.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px;\" \/>952 36 76 00<\/p>\n<p><a href=\"mailto:info@ibima.eu\" data-linkindex=\"0\" id=\"LPlnk315329\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/email.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px;\" \/>info@ibima.eu<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][dsm_menu title=\u00bbAPARTADOS PRINCIPALES\u00bb menu_id=\u00bb1332&#8243; menu_link_text_color=\u00bb#FFFFFF\u00bb active_link_color=\u00bb#FFFFFF\u00bb menu_link_text_active_color=\u00bb#FFFFFF\u00bb menu_link_text_visited_color=\u00bb#FFFFFF\u00bb list_style_type=\u00bbnone\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_align=\u00bbleft\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb20px\u00bb custom_margin_tablet=\u00bb200px||||false|false\u00bb custom_margin_phone=\u00bb0px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_menu][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][dsm_menu title=\u00bbTEXTOS LEGALES\u00bb menu_id=\u00bb1333&#8243; menu_link_text_color=\u00bb#FFFFFF\u00bb active_link_color=\u00bb#FFFFFF\u00bb menu_link_text_active_color=\u00bb#FFFFFF\u00bb menu_link_text_visited_color=\u00bb#FFFFFF\u00bb list_style_type=\u00bbnone\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_align=\u00bbleft\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb20px\u00bb custom_margin_tablet=\u00bb-155px||||false|false\u00bb custom_margin_phone=\u00bb0px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_menu][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_social_media_follow _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin_tablet=\u00bb5px||||false|false\u00bb custom_margin_phone=\u00bb5px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_social_media_follow_network social_network=\u00bbtwitter\u00bb url=\u00bbhttps:\/\/x.com\/_ibima?lang=es%20&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#000000&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]twitter[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbfacebook\u00bb url=\u00bbhttps:\/\/www.facebook.com\/Ibima.eu\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#3b5998&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]facebook[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbinstagram\u00bb url=\u00bbhttps:\/\/www.instagram.com\/ibima_mlg\/\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#ea2c59&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]instagram[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bblinkedin\u00bb url=\u00bbhttps:\/\/es.linkedin.com\/company\/ibima\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#007bb6&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]linkedin[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbyoutube\u00bb url=\u00bbhttps:\/\/www.youtube.com\/channel\/UCY3UUZTi9X0ur-1Gd6MKonw\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#a82400&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]youtube[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][dsm_icon_list _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbBuz\u00f3n de sugerencias\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/ibima.eu\/es\/comunicacion-con-el-instituto\/\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.2&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][dsm_icon_list_child text=\u00bbBuz\u00f3n de denuncias\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/ibima.eu\/es\/canal-de-denuncias\/\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbSuscr\u00edbete al Canal de Divulgaci\u00f3n\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/forms.gle\/5mczd4KKMqkBPdBy7&#8243; url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][\/dsm_icon_list][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Asociaci\u00f3n Europea EP PerMed ha anunciado la convocatoria transnacional CGT4PM2027 \u2013 Cell and Gene Therapy for Personalised Medicine, destinada a financiar proyectos internacionales de investigaci\u00f3n innovadora centrados en el desarrollo y validaci\u00f3n de nuevas terapias celulares y g\u00e9nicas aplicadas a la medicina personalizada.Los proyectos deber\u00e1 abordar el desarrollo y validaci\u00f3n de terapias celulares y [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-58129","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EP PerMed - CGT4PM2027 - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/ep-permed-cgt4pm2027\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EP PerMed - CGT4PM2027 - Ibima\" \/>\n<meta property=\"og:description\" content=\"La Asociaci\u00f3n Europea EP PerMed ha anunciado la convocatoria transnacional CGT4PM2027 \u2013 Cell and Gene Therapy for Personalised Medicine, destinada a financiar proyectos internacionales de investigaci\u00f3n innovadora centrados en el desarrollo y validaci\u00f3n de nuevas terapias celulares y g\u00e9nicas aplicadas a la medicina personalizada.Los proyectos deber\u00e1 abordar el desarrollo y validaci\u00f3n de terapias celulares y [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/ep-permed-cgt4pm2027\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-06T11:27:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/\",\"name\":\"EP PerMed - CGT4PM2027 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\",\"datePublished\":\"2025-11-06T11:16:20+00:00\",\"dateModified\":\"2026-11-06T11:27:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\",\"contentUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/ep-permed-cgt4pm2027\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EP PerMed &#8211; CGT4PM2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EP PerMed - CGT4PM2027 - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/ep-permed-cgt4pm2027\/","og_locale":"en_GB","og_type":"article","og_title":"EP PerMed - CGT4PM2027 - Ibima","og_description":"La Asociaci\u00f3n Europea EP PerMed ha anunciado la convocatoria transnacional CGT4PM2027 \u2013 Cell and Gene Therapy for Personalised Medicine, destinada a financiar proyectos internacionales de investigaci\u00f3n innovadora centrados en el desarrollo y validaci\u00f3n de nuevas terapias celulares y g\u00e9nicas aplicadas a la medicina personalizada.Los proyectos deber\u00e1 abordar el desarrollo y validaci\u00f3n de terapias celulares y [&hellip;]","og_url":"https:\/\/ibima.eu\/en\/ep-permed-cgt4pm2027\/","og_site_name":"Ibima","article_modified_time":"2026-11-06T11:27:50+00:00","og_image":[{"url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/","url":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/","name":"EP PerMed - CGT4PM2027 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/#primaryimage"},"image":{"@id":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","datePublished":"2025-11-06T11:16:20+00:00","dateModified":"2026-11-06T11:27:50+00:00","breadcrumb":{"@id":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/#primaryimage","url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","contentUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/es\/ep-permed-cgt4pm2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"EP PerMed &#8211; CGT4PM2027"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/58129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=58129"}],"version-history":[{"count":15,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/58129\/revisions"}],"predecessor-version":[{"id":64096,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/pages\/58129\/revisions\/64096"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=58129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}